Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Huntingtin mRNA is the messenger RNA that encodes the huntingtin (HTT) protein, which plays a crucial role in various cellular functions and is associated with Huntington's disease (HD) when mutated. It contains a CAG repeat sequence, which, when expanded, leads to the production of mutant HTT protein and the development of HD. Targeting HTT mRNA is a therapeutic strategy for treating Huntington's disease.
Antisense oligonucleotides bind to HTT mRNA and promote its degradation. RNA interference uses small interfering RNAs to target HTT mRNA for degradation. Zinc-Finger Transcriptional Repressors aim to reduce transcription of the HTT gene. CRISPR/Cas9 methods also aim to reduce transcription by targeting the DNA directly.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Huntingtin mRNA (HTT mRNA).